Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial
This small study; looking at non-diabetic patients with ovarian cancer, half of whom received metformin in addition to normal platinum based chemo, the others chemo alone; showed no progression free survival benefit.
Type two diabetic patients have a lower incidence of tumour development than healthy controls and those diabetic patients, treated with metformin, who are diagnosed with cancer, have a lower mortality.
A recent hypothesis proposes that primary non-hereditary ovarian cancer risk factors are increased through the development of ovarian fibrosis. Metformin, which reduces fibrosis, may be protective.
https://tinyurl.com/yy4ytghy
No comments:
Post a Comment